Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that audio recording of Analyst and Investor Conference Call for Audited financial results for the quarter and financial year ended March 31, 2022 held on Tuesday, May 17, 2022, has been uploaded on the Company''s website. The link to access the audio call recording is: https://jubilantingrevia.com/investors/financials/quarterly-results. This is for your information and records.
18-05-2022
Bigul

Annual report for Jubilant Ingrevia Ltd. for FY-2022
18-05-2022

Earnings Call for Q4FY22 of Jubilant Ingrevia

 Conference Call with Jubilant Ingrevia Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
17-05-2022
Bigul

Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Change in Directorate

 We wish to inform that the Board of Directors of the Company has, at its meeting held today i.e. Tuesday, May 17, 2022, considered and approved the following proposals: 1. Appointment of Mr. Anil Khubchandani as Co-CEO & Whole-time Director of the Company effective from May 17, 2022 for a period of 5 years. Mr. Khubchandani is not related to any Director of the Company. Brief profile of Mr. Khubchandani is given in Annexure-I. In terms of SEBI Letter dated June 14, 2018 read with NSE Circular No. NSE/CML/2018/24 dated June 20, 2018, we wish to confirm that Mr. Anil Khubchandani is not debarred from holding the office of Director by virtue of any SEBI order or any other authority. 2. Resignation of Mr. Anant Pande as Director and Whole-time Director of the Company effective from the close of business hours of May 17, 2022. This is for your information and record.
17-05-2022
Bigul

Jubilant Ingrevia Ltd - 543271 - Board Meeting Outcome for Outcome Of Board Meeting - Dividend

 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on May 17, 2022, recommended final dividend of Rs. 2.50 (Rupees Two and Fifty Paisa) per equity share of Re.1 each for the year ended March 31, 2022. The dividend, if approved by the shareholders at the ensuing Annual General Meeting of the Company, will be paid / dispatched on or before September 8, 2022. We request you to take the same on record.
17-05-2022
Bigul

Q4FY22 Quarterly Result Announced for Jubilant Ingrevia Ltd.

 Pharmaceuticals firm Jubilant Ingrevia declares Q4FY22 result: Revenue grew by 20% on YoY basis, driven by growth in Speciality Chemicals and Chemical intermediate product segments. Speciality Chemicals revenue grew by 35% YoY driven by volume growth across products Nutrition and Health Solutions business improved the prices in challenging market conditions during the quarter. Chemical Intermediates revenue grew by 18% YoY, driven by higher prices of products EBITDA at Rs 152 Crore is lower, mainly due to impact of Acetic acid prices on our inventory, while sharp increase in key input prices for Speciality Chemicals and Nutrition & Health Solutions segment were passed on partially till end of quarter. However overall impact of Acetic Acid price on profitability for full year FY’22 was not significant. PAT declined by 28% YoY driven by decline in EBITDA, as explained above. ROCE for FY22 improved to 27.8% as against 20.2% in FY21. ROE during FY22 stood at 21.9% as against 16.4% in FY21. Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, CoChairman, Jubilant Ingrevia Limited said: “We are pleased to announce that we delivered record financial performance during FY’2022 despite facing severe second wave of pandemic at beginning of the year and then headwinds and volatility in key input raw material and energy prices since last three quarters. We also maintained steady growth in Q4’FY22. In our Specialty Chemicals segment we delivered strong growth led by healthy demand across industry segment. We are also pleased to share that we successfully commissioned Phase-1 of Diketene and Derivatives manufacturing unit at our Gajraula facility. In Nutrition & Health Solution we improved our profitability due to higher price realization and improved volume in North America. In Chemical Intermediates Segment, we continued the higher sales with Pharmaceutical and Agrochemical customers and recorded healthy growth in the EU. Though profitability of the Acetyls business during Q4 was impacted due to sharp and consistent correction in Acetic Acid prices impacting our inventory, the overall impact of Acetic Acid price on profitability for full year FY’22 was not significant. Our business team continue to work closely with customers to ensure that the increase in input cost is passed on quickly and our supply chain team ensures the uninterrupted supplies and timely deliveries. Due to advancement in our new product pipelines & CDMO projects, we are pleased to revise our investment plan for growth projects to Rs. 2050 Crore, out of this we have already committed investment in projects worth Rs. 800 Crore till date and now we plan to invest about Rs. 1,250 Crore. to be committed between FY’23 & FY’24. These investments will be funded through internal accruals and all these new facilities should be ready for operations by FY’25 We are also glad to share that the Board has recommended a final dividend of 250% i.e. Rs 2.5 per equity share of face value of Re 1 each for the FY’22. This shall result in cash outflow of Rs 39.8 Crore. During the year company has already declared an interim dividend of 250% i.e. Rs. 2.5 per equity share of Rs 1 each and the total dividend for FY’22 works out to be 500% i.e Rs 5.0 Per equity share of Rs 1 each amounting to Rs 79.6 Crore of Cash outflow. We remain fully committed towards the growth aspirations envisioned for the company, and are excited to realise the emerging opportunities going forward in our business segments”. Result PDF
17-05-2022
Bigul

Jubilant Ingrevia Ltd - 543271 - Financial Results - March 31, 2022

 In terms of Regulations 33 and 52 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2022 were approved by the Board of Directors of the Company at its meeting held today at 01:30 pm and concluded at 3.50 pm. We request you to take the same on record.
17-05-2022
Bigul

Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Issue of Securities

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has issued Commercial Papers ('CPs') of Rs. 50 Crore on May 13, 2022. Details of the same are mentioned i the enclosed document.
16-05-2022
Bigul

Jubilant Ingrevia Ltd - 543271 - Board Meeting Outcome for Outcome Of Finance Committee Meeting

 In terms of Regulation 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Finance Committee of the Board of Directors has, at its meeting held on Friday, May 13, 2022 (commenced at 03:00 pm and concluded at 03:40 pm), approved early redemption and change in payment terms of 1,000 (One Thousand) 7.90% Secured Rated Listed Redeemable Non-Convertible Debentures (ISIN: INE700A07089) of Rs. 10,00,000 each aggregating to Rs. 100 Crore. We request you to take the same on record.
13-05-2022
Bigul

Jubilant Ingrevia Ltd - 543271 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that a share certificate has been reported to be lost. We have received request from Mr. Dipakkumar Kantilal Modi, the joint holder of the Share Certificate, for issuance of Duplicate Share Certificate in lieu of the original. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record.
11-05-2022
Next Page
Close

Let's Open Free Demat Account